Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at firstname.lastname@example.org
Air Pollution, Increased Homocysteine Levels Exacerbates Dementia Risk
Results indicated a substantial direct effect of air pollution on dementia suggesting that air pollution affects the development of dementia through multiple pathways.
Slight Association Identified Between Cerebral Microbleeds and Acute Symptomatic Seizures
Stroke of an undetermined cause was associated with acute symptomatic seizures, an effect that was marginally mediated by cerebral microbleeds.
Nexalin Neurostimulation Device Shows Therapeutic Benefit in Migraine
Patients treated with the neuromodulation device outperformed those on placebo on several key outcomes, including Visual Analog Scale and Migraine-Specific Quality of Life Questionnaire scores.
Amyloid Vaccine UB-311 Demonstrates Positive Findings With No ARIA-E Cases in Published Phase 2 Study
UB-311 elicited a robust, rapid, and titrated antibody response to amyloid-ß, with an overall 97% responder rate that was maintained by 93% of the cohort by the end of the 78-week study.
Episode 95: Expanding Potential for Long-Term Treatment in SMA
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Crawford, MD. [LISTEN TIME: 24 minutes]
Alzheimer Agent ACD856 Shows Promise in Early-Stage Trial
Pharmacokinetic results indicated that ACD856 has a suitable pharmacokinetic profile for further development with a rapid absorption, dose-dependent exposure, and a favorable metabolic profile.
Clinical Study of Fibromyalgia-Type Long COVID Agent Completed, Results to Come Soon
The double-blind, placebo-controlled trial assesses change from baseline in the weekly average of daily self-reported worst pain intensity scores after 14 weeks of treatment.
Essential Tremor Agent Ulixacaltamide Continues to Show Positive Results in Essential1 Study
Patients who continued on active treatment into the open-label extension saw continued improvements in their condition after 14 weeks.
Argenx Reports Positive Findings in ADHERE Study of Chronic Inflammatory Demyelinating Polyneuropathy
Results showed that 67% of treated patients in Stage A demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP.
Slight Increased Risk of Premature Myocardial Infarction and Hemorrhagic Stroke Observed in Women With Migraine
In a large-scale, nationwide cohort, the impact of migraine on risk of premature myocardial infarction was slightly greater for women and may potentially only exist for women.
NeuroVoices: Bruce Bebo, PhD, on Expanding MS Research Through the Pathways to Cures Roadmap
The executive vice president of the National MS Society provided insight on the Pathways to Cures roadmap, a global initiative to stop multiple sclerosis, restore function, and end MS.
Low-Dose Aspirin Linked With Increased Intracranial Bleeding Risk in Older Adults
In comparison with placebo, older adults on low-dose aspirin had an increase in a combination of subdural, extradural, and subarachnoid bleeding.
Amyloid-Negative, Tau-Positive Profiles Not Associated With Increased Cognitive Decline
Concentrations of Aß42 and Aß40 were substantially higher in those with amyloid-ß-negative, tau-positive status compared with Aß-negative, tau-negative patients.
Ceribell’s Status Epilepticus Software Receives FDA Clearance With CMS NTAP Coverage Included
With the decision, ClarityPro becomes the first and only device to offer new technology add-on payment reimbursement for the diagnosis of electrographic status epilepticus.
Patient Dosing Commenced in Phase 1/2 Gene Therapy Trial of Limb-Girdle Muscular Dystrophy Type 2I/R9
The trial is expected to include 14 individuals with genetically confirmed limb-girdle muscular dystrophy who will be randomly assigned 1:1 to either AB-1003 or placebo for a year-long treatment period.
FDA Accepts New Drug Application for Long-Acting Form of Glatiramer Acetate
In the supporting phase 3 study, treatment with GA Depot resulted in statistically significant reductions in annualized relapse rate, the primary end point, and other secondary outcomes of T1 and T2 hyperintense lesions.
Incident Epilepsy and Antiseizure Medications Independently Associated With Osteoporosis Risk in Adults
The time to osteoporosis was 23% faster with exposure to non-enzyme-inducing antiseizure medications and 9% faster for enzyme-inducing ASMs, independent of epilepsy.
Tirofiban Associated With Higher Likelihood of Excellent Poststroke Outcome Than Aspirin
Although treatment with tirofiban improved the odds of excellent outcome, results for the secondary end points did not consistently support the primary end point analysis.
Long-Term Follow-Up of Natalizumab-Treated Patients Provides Insights to Trends in Prescription Patterns, Effectiveness
After nearly 13 years of follow-up, 36% of patients with relapsing multiple sclerosis had a confirmed Expanded Disability Status Scale score worsening.
Combination of Digital CBT and Traditional Medications Improves Insomnia, With Questions About Long-Term Sustainability
The combination of digital cognitive behavioral therapy and medication resulted in a sustained improvement in sleep quality compared with monotherapy modalities.
Positive Phase 1 Data on Gut-Targeting Therapy in Neurodegenerative Diseases Announced
Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.
NeuroVoices: Thomas Crawford, MD, on Continued Benefit of Early Initiated Nusinersen in SMA
The pediatric neurologist at Johns Hopkins Medicine provided clarity on the recently published 5-year update of the NURTURE study, and the importance of treating spinal muscular atrophy at its presymptomatic stages.
Sleep Consolidation and Sleep Apnea, Not Sleep Stage Percentages, Associated With Cognition
Sleep stage percentages were not associated with global cognition across cohorts, while patients with mild to severe OSA displayed poorer global cognitive function.
Phase 3 Study of Pitolisant in Prader-Willi Syndrome Updates Following Positive FDA Meeting
Harmony aligned with the FDA on the proposed phase 3 design elements, which is expected to kick off later this year.
Biological Effects Seen in Small Scale Study of Remyelinating Agent for MS
The findings provided safety and tolerability data for using liothyronine in future, larger studies of multiple sclerosis, with the potential to be observed in combination with other therapies.
Thrombolytic Agent Recombinant Human Prourokinase Noninferior to Alteplase in Stroke Treatment
Intravenous thrombolysis with recombinant human prourokinase resulted in a 16.4% lowered risk of systemic bleeding in comparison with alteplase treatment, which was consistent with previous phase 2 data.
World Health Organization Adds Several MS Treatments to List of Essential Medicines
With the new update, cladribine, glatiramer acetate, and rituximab, are now included in the Lists of Essential Medicines, filing a gap given the global burden of multiple sclerosis.
Potential of Vidofludimus Calcium as a Nurr1 Activator
Andreas Muehler, MD, and Hella Kohlhof, PhD, provided answers on a recently published analysis showing considerable activation of nuclear receptor related 1 with vidofludimus calcium, an agent in development for various forms of multiple sclerosis.
Increased New-Onset Cardiovascular Risk Observed in Narcolepsy
The findings confirmed and expanded upon existing literature by demonstrating that the incidence rates of multiple cardiovascular events, including stroke, heart failure, and cardiovascular disease, are significantly higher in patients with narcolepsy.
Episode 94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive commentary from Alberto J. Espay, MD, PhD, and Anton P. Porsteinsson, MD. [LISTEN TIME: 48 minutes]
2 Clarke Drive Cranbury, NJ 08512